Pricing & Availability

How much will pet GLP-1 cost, and when can you actually get it?

No pet GLP-1 drug is FDA-approved or on sale yet, so there is no official price to quote. Okava has guided to a roughly $100 per month-equivalent retail target for its OKV-119 cat implant. Adding the second candidate and vet fees, the realistic all-in cost lands around $600 to $1,500 per year. These will be prescription drugs dispensed through your veterinarian, not over-the-counter or human telehealth products. The earliest realistic availability is late 2027 for cats and 2028 to 2030 for dogs, and only if the trials succeed.

Nothing here is a confirmed price.Neither Okava nor Akston has announced official pricing. Every figure below is an estimate drawn from public company guidance and veterinary-pharma analyst comparisons. We update this page the day real pricing is announced.

What each drug is expected to cost

DrugFormatEstimated priceStatus
Okava OKV-119 (cats)~6-month implant~$100/mo-equivalent (about $600 per implant), per Okava guidanceTrial, readout summer 2026
Akston AKS-562c (cats)Weekly injectionEst. $25 to $50 per dose ($108 to $216/mo), analyst estimateCornell trial, no public price
Canine GLP-1 (dogs)Not yet in trialsNo basis for an estimate yetPre-clinical, 2028 to 2030

How it will be distributed

These are prescription veterinary medications. Expect them to be prescribed and dispensed the way other long-acting vet drugs are: through your veterinarian or a veterinary pharmacy, after an exam and a body-condition assessment. There is no over-the-counter path and no human-telehealth path for a pet GLP-1.

Industry analysts expect pricing to follow the subscription-preventative model already used by medications like Bravecto (flea and tick) and ProHeart (heartworm), which typically run $80 to $150 per quarterly or annual dose. A long-acting implant or a weekly injection fits that recurring-cost pattern rather than a one-time purchase.

When you can actually get it

For the full milestone-by-milestone view, see the Okava and Akston pipeline tracker. To be told the day pricing and availability are announced, get on the launch alert list.

Pricing FAQ

How much will pet GLP-1 cost?+
Neither Okava nor Akston has announced official pricing. Okava has publicly guided to a roughly $100/month-equivalent retail target for its OKV-119 cat implant. Analysts expect long-acting pet GLP-1 drugs to follow the subscription-preventative model used by medications like Bravecto and ProHeart, which run roughly $80 to $150 per quarterly or annual dose.
What is the total yearly cost for an owner?+
Best current estimate is $600 to $1,500 per year for the medication alone, plus veterinary visit fees (initial consultation, body-condition scoring, and periodic monitoring). Actual cost will depend on the final drug, the dosing format, and competitive dynamics once more than one product is on the market.
Will I be able to buy it over the counter?+
No. These are prescription veterinary drugs. They will be prescribed and dispensed through your veterinarian or a veterinary pharmacy, not sold over the counter or through human telehealth. A vet exam and a body-condition assessment will almost certainly be required first.
When can I actually get it?+
Cats first. Even in a best case, no FDA-approved cat GLP-1 is realistic before late 2027, more likely 2027 to 2028. For dogs, the realistic window is 2028 to 2030. Availability depends entirely on the trials succeeding and FDA review, which typically takes 12 to 18 months after a positive readout.

Note on pricing: No pet GLP-1 medication is approved or for sale as of the update date. Every price on this page is an estimate based on public company guidance and veterinary-pharmaceutical analyst comparisons, not a confirmed retail price. This page is informational and is not veterinary advice.